Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Delcath Systems, Inc. (DCTH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.5100+0.0600 (+1.35%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.4500
Open4.5899
Bid2.8000 x 1100
Ask5.3900 x 1200
Day's Range4.4100 - 4.5899
52 Week Range4.3000 - 13.5000
Volume18,400
Avg. Volume25,754
Market Cap33.177M
Beta (5Y Monthly)0.55
PE Ratio (TTM)N/A
EPS (TTM)-4.2520
Earnings DateMar 29, 2022 - Apr 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.20
  • GlobeNewswire

    Delcath Systems Reports First Quarter 2022 Results and Provides Business Update

    NEW YORK , May 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the first quarter ended March 31, 2022. Recent Business Highlights During and since the first quarter, Delcath: Held a pre-NDA meeting with FDA and announced plans to file an NDA in the third quarter of 2022,Announced the acceptance of a poster pres

  • GlobeNewswire

    Delcath Announces Poster Presentation at the 2022 ASCO Annual Meeting

    NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the acceptance of a poster presentation at the upcoming American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, to be held in-person on June 3-7, 2022, in Chicago, Illinois. Title: FOCUS Phase 3 Trial Results: Percutaneous Hepatic Perfusion (PHP) With Melphalan for Patients With Ocula

  • Simply Wall St.

    Is Delcath Systems (NASDAQ:DCTH) Using Too Much Debt?

    Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Advertisement
Advertisement